Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.38 |
| ▸ | CDK1 | P06493 | 4/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.38 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.38 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127006 | 0.85 | AMY1A (0.43) | TGFBR1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL2127203 | 0.78 | PRKD3 (0.47) | TGFBR1PRKD3PRKD1PRKD2PTGES | |
| SCHEMBL2125635 | 0.78 | IDO1 (0.47) | GSK3BPTGES | |
| SCHEMBL2130089 | 0.72 | MGAM (0.47) | GSK3BPIM1 | |
| SCHEMBL2128318 | 0.67 | KDM4E (0.53) | CYP1A2CYP3A4KMO | |
| SCHEMBL4152308 | 0.66 | GSK3B (0.45) | PRKD3PRKD2CDK1GSK3BGSK3A | |
| SCHEMBL12424812 | 0.66 | ADORA2A (0.58) | — | |
| SCHEMBL2128130 | 0.65 | IP6K1 (0.34) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL2128866 | 0.65 | CYP2A6 (0.42) | TGFBR1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL3841205 | 0.64 | APEX1 (0.35) | TGFBR1PTGESCYP1A2CYP3A4APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-9290502-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-22 | — | — | US | disclosed |
| EP-1881834-B1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN R & D IRELAND (IE) | 2012-04-25 | — | — | EP | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| EP-1881834-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.